GlassScriptPhysician profile
Peggy B Taylor
NPI 1922094135
$11,134.42
in general payments reported to CMS, 2019-2025
47 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $1,558 · 2021: $1,449 · 2022: $1,526 · 2023: $1,184 · 2024: $1,539 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,674 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,674.21 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,817.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $799.47 | 2019-2022 | |
| Lilly USA, LLC | $570.79 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $509.38 | 2019-2022 | |
| Pfizer INC. | $475.72 | 2019-2023 | |
| Abbvie INC. | $463.69 | 2021-2025 | Vraylar |
| Aimmune Therapeutics, INC. | $462.82 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.70 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $434.42 | 2020-2024 | Watchman Access System |
| Merck Sharp & Dohme LLC | $411.03 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Biohaven Pharmaceuticals, INC. | $338.54 | 2020-2021 | |
| Exact Sciences Corporation | $312.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $276.80 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $233.20 | 2019-2020 | |
| Amarin Pharma, INC. | $230.80 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.